Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update
Main Article Content
Keywords
Ankylosing spondylitis, anti-TNF-α, IL-17 inhibitors, JAK inhibitors
Abstract
Background: Ankylosing spondylitis (AS), a long-term autoimmune disorder characterized by systemic inflammation, manifests as gradually worsening arthritis predominantly affecting the spinal column and sacroiliac joints. While emerging biologic agents have broadened treatment possibilities, their clinical application raises notable safety considerations.
Objective: To comprehensively summarize recent advancements in bDMARD applications (including tumor necrosis factor-alpha inhibitors (TNFi), interleukin 17 inhibitors (IL17i), and Janus kinase inhibitors (JAKi)) for AS management.
Material and Methods: A thorough bibliographic search was conducted to identify studies meeting the inclusion criteria in the Pubmed (MEDLINE) and EMBASE databases in July 2025 for nearly a year. Our search strategy included both medical subject headings (MeSH) and free text terms relevant to the biologics.
Results: A total of 147 studies were screened and 37 clinical studies were ultimately selected in this review, drawing on peer-reviewed studies released within the previous calendar year. Adalimumab, infliximab, etanercept, golimumab, certolizumab pegol, secukinumab, bimekizumab, ixekizumab, tofacitinib, upadacitinib, and baricitinib had greater remittance in AS, with some side effects.
Conclusion: This comprehensive analysis assesses therapeutic outcomes and adverse effects of TNFi, IL17i, and JAKi in AS care.
References
1 Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: An autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021;17(7):387-404. 10.1038/s41584-021-00625-y
2 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. 10.1016/s0140-6736(16)31591-4
3 Jethwa H, Bowness P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: New advances and potentials for treatment. Clin Exp Immunol. 2016;183(1):30–36. 10.1111/cei.12670
4 Kim SH, Lee SH. Updates on ankylosing spondylitis: Pathogenesis and therapeutic agents. J Rheum Dis. 2023;30(4):220–33. 10.4078/jrd.2023.0041
5 Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66(2):231–41. 10.1002/art.38291. PMid: 24504793
6 Chen L, Al-Mossawi MH, Ridley A, Sekine T, Hammitzsch A, de Wit J, et al. miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis. Ann Rheum Dis. 2017;76(3):620–5. 10.1136/annrheumdis-2016-210175. PMid: 28039186.
7 Won EJ, Kim HJ, Lee YJ, Kim MJ, Lee HI, Jang HH, et al. CCL20 inhibition for treating inflammation in ankylosing spondylitis. Rheumatology (Oxford). 2023;62(12):4000–5. 10.1093/rheumatology/kead268
8 Yi K, Jo S, Song W, Lee HI, Kim HJ, Kang JH, et al. Analysis of single-cell transcriptome and surface protein expression in ankylosing spondylitis identifies OX40-positive and glucocorticoid-induced tumor necrosis factor receptor-positive pathogenic Th17 cells. Arthritis Rheumatol. 2023;75(7):1176–86. 10.1002/art.42476
9 Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650–7. 10.1093/rheumatology/ket387
10 Giray E, Yağcı İ. Cardiac rehabilitation in a patient with ankylosing spondylitis: A single-program, double-effect. Turk J Phys Med Rehabil. 2019;65(2):194–7. 10.5606/tftrd.2019.2401
11 Ozen S, Ozen A, Unal EU, Tufekcioglu O, Ataman S, Yalcin AP. Subclinical cardiac disease in ankylosing spondylitis. Echocardiography. 2018;35(10):1579–86. 10.1111/echo.14103
12 Linguang Z, Bin J. Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis. J Chinese Pharmaceut Sci. 2018;27(1):59–63. 10.5246/jcps.2018.01.007
13 Ke M, Liu W, Lu H, Pan X, Wu M, Qi N, et al. Breaking boundaries in ankylosing spondylitis: How innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges. Front Immunol. 2025;16:1613502. 10.3389/fimmu.2025.1613502
14 Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 Update. Ann Rheum Dis. 2023;82(1):19–34. 10.1136/ard-2022-223296
15 Martínez-Ramos S, Rafael-Vidal C, Pego-Reigosa JM, García S. Monocytes and macrophages in spondyloarthritis: Functional roles and effects of current therapies. Cells. 2022;11(3):515. 10.3390/cells11030515. PMid: 35159323.
16 Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis—A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. 10.1016/j.semarthrit.2022
17 Garcia-Montoya L, Emery P. Disease modification in ankylosing spondylitis with TNF inhibitors: Spotlight on early phase clinical trials. Expert Opin Investig Drugs. 2021;30(11):1109–24. 10.1080/13543784.2021.2010187
18 Zouris G, Evangelopoulos DS, Benetos IS, Vlamis J. The use of TNF-α inhibitors in active ankylosing spondylitis treatment. Cureus. 2024;16(6):e61500. 10.7759/cureus.61500
19 Kim A, So MW, Lee SG. Association of the driving distance, driving time, and public transit time to the hospital with the persistence of tumor necrosis factor inhibitors in patients with ankylosing spondylitis: A retrospective cohort study. Patient Prefer Adherence. 2025;19:373–82. 10.2147/ppa.S504479
20 Walbaum M, Jana-Valencia N. Aggregate distributional cost-effectiveness analysis of biologics for the treatment of ankylosing spondylitis in Chile. Appl Health Econ Health Policy. 2025;23:905–918. 10.1007/s40258-025-00972-x
21 van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46. 10.1002/art.21913
22 Pelechas E, Voulgari PV, Drosos AA. Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opin Drug Discov. 2021;16(3):227–34. 10.1080/17460441.2021.1846516
23 Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, et al. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): A randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5(4):e215–24. 10.1016/s2665-9913(23)00070-x
24 Machado MA, Maciel AA, de Lemos LL, Costa JO, Kakehasi AM, Andrade EI, et al. Adalimumab in rheumatoid arthritis treatment: A systematic review and meta-analysis of randomized clinical trials. Rev Bras Reumatol. 2013;53(5):419–30.
25 Nakano S, Nakajima A, Sonobe M, Taniguchi S, Yamada M, Yamamoto K, et al. SAPHO syndrome with bone destruction in the lumbar vertebral endplates: A case report. Mod Rheumatol Case Rep. 2025;9(2). 10.1093/mrcr/rxaf013
26 Liu FC, Lu CH, Kuo CF, Liao HT, Lee SS, Su KY, et al. Clinical response to adalimumab therapy and its determinants in patients with radiographic axial spondyloarthritis: A prospective real-world study in Taiwan. Int J Rheum Dis. 2025;28(6):e70285. 10.1111/1756-185x.70285
27 Kwon OC, Lee HS, Yang J, Park MC. Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis. Rheumatology (Oxford). 2025;64(2):588–96. 10.1093/rheumatology/keae003
28 Mu X, Chen S, He C, Li H, Huang Z. Bartonella henselae and Aspergillus flavus coinfection in an immunocompromised patient. Diagn Microbiol Infect Dis. 2025;112(1):116708. 10.1016/j.diagmicrobio.2025.116708
29 Yetkin MF, Benli Ş, Mirza M. Progressive demyelinating disease associated with adalimumab treatment in a patient diagnosed with ankylosing spondylitis. Neurol India. 2025;73(4):791–3. 10.4103/neuroindia.NI_371_20
30 Kwon OC, Lee HS, Yang J, Paul T, Jin H, Lee Y, et al. Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea. Rheumatology (Oxford). 2025;64(6):3518–25. 10.1093/rheumatology/keaf038
31 Cui B, Lin J, Huang Y, Zhu H, Zou J, Qin J, et al. Case report: Dysgeusia, strawberry tongue, and psoriatic eruptions after combination treatment with adalimumab, sulfasalazine, and etoricoxib for ankylosing spondylitis. Front Med (Lausanne). 2025;12:1419922. 10.3389/fmed.2025.1419922
32 Ayari M, Mtir M, Mami I, Rais L, Ben Azouz S, Douggui H, et al. Tubulointerstitial nephritis in ANCA-associated vasculitis as a rare adverse effect of adalimumab: A case report. Curr Drug Saf. 2025;20. 10.2174/0115748863362460250220172535
33 Korkmaz D, Karakoç R, Altunbaş B, Demirtürk N. Candida meningitis accompanied by upper gastrointestinal tract candidiasis in an immunocompromised host. Infect Dis Clin Microbiol. 2025;7(1):97–101. 10.36519/idcm.2025.415
34 Zha M, Ding DD. Immunoglobulin A vasculitis and pustular psoriasis precipitated by Tawon Liar: A case report. J Med Case Rep. 2025;19(1):259. 10.1186/s13256-025-05167-5
35 R, Haughton JM, Goddard EJ, Courmier D, Radziszewski W, Meadows RH, et al. Real-world experience with an adalimumab biosimilar (ABP 501) in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis in Europe: Results from the adelphi disease specific programme. Rheumatol Ther. 2025; 12(3):469-492. 10.1007/s40744-025-00755-9
36 Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–87. 10.1136/annrheumdis-2016-210459
37 Wynne C, Altendorfer M, Sonderegger I, Gheyle L, Ellis-Pegler R, Buschke S, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25(12):1361–70. 10.1080/13543784.2016.1255724
38 Cheng X, Fu Z, Liu J, Cheng B, Shi R, Xu X, et al. Comparative real-world retention rate and safety of biosimilar IBI303 versus Humira in ankylosing spondylitis: A retrospective study. Medicine (Baltimore). 2025;104(26):e43010. 10.1097/md.0000000000043010
39 Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443–53. 10.1016/0161-5890(93)90106-l
40 Deepa AR, Jaleel AA, Ancil A, Debbarma S, Thampi T. Concurrent psoriatic arthritis and ankylosing spondylitis in a middle-aged man: A case report with peripheral joint functional and quality of life assessment. Cureus. 2025;17(2):e79826. 10.7759/cureus.79826
41 Alnaqbi KA, Riaz A, Alaswad M. Paradoxical inflammatory bowel disease induced by golimumab in a patient with ankylosing spondylitis: A case report and systematic review. Cureus. 2025;17(1):e77363. 10.7759/cureus.77363
42 Furusawa H, Shimada S, Sawada A, Tanaka K, Yamamoto K, Miyazaki Y. Composite lymphoma after treatment with infliximab for sarcoidosis and ankylosing spondylitis. Intern Med. 2025;64(1):129–32. 10.2169/internalmedicine.3274-23
43 Moyón M, Añazco JS, Vásconez AE, Larreategui D, Torres MB, Moyón N, et al. Abdominal tuberculosis in a patient with ankylosing spondylitis and infliximab: Is the risk still too great? A case report. J Surg Case Rep. 2025;2025(6):rjaf422. 10.1093/jscr/rjaf422
44 Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis. 2012;71(10):1593–5. 10.1136/annrheumdis-2012-201844
45 Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: Pooled analysis of long-term safety and effectiveness. Adv Ther. 2021;38(8):4366–87. 10.1007/s12325-021-01834-3
46 Kim Y, Choi N, Shin JH, Jo S, Nam B, Kim TH. Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13. J Rheum Dis. 2025;32(2):136–44. 10.4078/jrd.2024.0114
47 Marotte H, Cantagrel A, Coury F, Schaeverbeke T, Assing M, Kessouri M, et al. Real-world effectiveness and safety of infliximab biosimilar CT-P13 for rheumatic diseases: A National Observational Cohort Study (ReFLECT). Adv Ther. 2025;42:4659–4680. 10.1007/s12325-025-03304-6
48 Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56. 10.1056/NEJMoa012664
49 Hassett B, Singh E, Mahgoub E, O’Brien J, Vicik SM, Fitzpatrick B. Manufacturing history of etanercept (Enbrel(®)): Consistency of product quality through major process revisions. MAbs. 2018;10(1):159–65. 10.1080/19420862.2017.1388483
50 Tichý Š, Nekvindová L, Baranová J, Vencovský J, Pavelka K, Horák P, et al. Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A propensity score-matched analysis from the Czech ATTRA registry. Scand J Rheumatol. 2025;54(2):79–86. 10.1080/03009742.2024.2381746
51 Tanchuling RV, Lopez JS, Maliwat RD. Coexistent ankylosing spondylitis and ocular toxocariasis in a pediatric patient manifesting as bilateral panuveitis. Cureus. 2025;17(4):e82767. 10.7759/cureus.82767
52 Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010;2(4):428–39. 10.4161/mabs.12304
53 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): Where we stand today. Hum Vaccin Immunother. 2021;17(6):1586–98. 10.1080/21645515.2020.1836919
54 Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, et al. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther. 2022;24(1):73. 10.1186/s13075-022-02753-6
55 Yu X, Zhong J, Zhuang X, Lin Z, Fu H, Zhang Y. Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: A real-world retrospective and pharmacovigilance study. Front Pharmacol. 2025;16:1533902. 10.3389/fphar.2025.1533902
56 Dhillon S. Certolizumab pegol: A review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014;74(9):999–1016. 10.1007/s40265-014-0239-z
57 Vieujean S, Peyrin-Biroulet L. Triple biologic therapy for refractory Crohn’s disease. J Crohns Colitis. 2025;19(5). 10.1093/ecco-jcc/jjaf067. PMid: 40251965.
58 Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity. 2015;43(4):739–50. 10.1016/j.immuni.2015.08.019
59 Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269–73. 10.1007/s10067-010-1647-4
60 Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–32. 10.1136/annrheumdis-2017-212127
61 van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 Week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–51. 10.1016/s0140-6736(18)31946-9
62 van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79(5):595–604. 10.1136/annrheumdis-2020-216980
63 Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48. 10.1056/NEJMoa1505066
64 Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–20. 10.1002/art.41477
65 Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285. 10.1186/s13075-017-1490-y
66 Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-Week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447–62. 10.1007/s40744-018-0123-5
67 Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: Results from the 52-week, phase III China-centric study, MEASURE 5. Chin Med J (Engl). 2020;133(21):2521–31. 10.1097/cm9.0000000000001099
68 Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, et al. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford). 2025; 64(4):1864–1872. 10.1093/rheumatology/keae432
69 Bounas A, Kandyli A, Katsifi G, Boumpa D, Tektonidou MG, Gazi S, et al. High long-term retention rates of Secukinumab in psoriatic arthritis and ankylosing spondylitis: A 3-year interim analysis from the observational, prospective SERENA study, in Greek patients. Rheumatol Int. 2025;45(5):105. 10.1007/s00296-025-05839-x
70 Felis-Giemza A, Stasiek M, Palej K, Wysmołek-Sołtysik M, Łosoś M, Stańczyk S, et al. Real-world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland. Sci Rep. 2025;15(1):25212. 10.1038/s41598-025-11070-2
71 Neycheva S, Kamburova A. IL-17 Inhibitor secukinumab achieves remission in relapsing polychondritis: A case report. Am J Case Rep. 2025;26:e946916. 10.12659/ajcr.946916
72 Dikmetas O, Kapucu Y, Coşan S, Rustamova N, Ozsoy Z, Kocabeyoglu S, et al. Systemic secukinumab treatment in patients with ankylosing spondylitis: The relationship between systemic and tear proinflammatory cytokines and ocular surface findings—A pilot study. Clin Rheumatol. 2025;44(7):2775–2782. 10.1007/s10067-025-07492-y
73 Li M, Wu P, Yong SB, Leong PY. Case report: Successful treatment of secukinumab-induced SAPHO syndrome with tofacitinib. Int J Rheum Dis. 2025;28(6):e70305. 10.1111/1756-185x.70305
74 Bezerra HKF, Penafort PVM, Alves FA, Prado JD, Vargas PA. First case report of oral histoplasmosis in a patient receiving secukinumab (Cosentyx): Opportunistic infections as complication of emerging immunomodulatory therapies. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025;140(3):e64–e68. 10.1016/j.oooo.2025.04.096
75 van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: Results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515–26. 10.1136/ard-2022-223595
76 Deodhar A, Navarro-Compán V, Poddubnyy D, Gensler LS, Ramiro S, Tomita T, et al. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-Year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 2025;11(1):e005081. 10.1136/rmdopen-2024-005081. PMid: 39890205.
77 Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase iii randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611. 10.1002/art.40753
78 Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85. 10.1136/annrheumdis-2019-216118
79 Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, et al. Ixekizumab for active radiographic axial spondyloarthritis in Chinese patients: 16-and 52-Week results from a phase III, randomized, double-blind, placebo-controlled study. BioDrugs. 2024;38(1):145–56. 10.1007/s40259-023-00625-2
80 Monguchi K, Nakashima C, Hino S, Otsuka A. Alopecia areata observed in a patient receiving ixekizumab: A case report. J Dermatol. 2025;52(7):e634–e636. 10.1111/1346-8138.17768
81 Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019;58(2):197–205. 10.1093/rheumatology/key070
82 Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059–67. 10.1136/ard-2023-224049
83 Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–75. 10.1136/annrheumdis-2020-219012
84 Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib—An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–28.
85 Norton H, Sliwinska-Stanczyk P, Hala T, El-Zorkany B, Stockert L, Mundayat R, et al. Tofacitinib efficacy/safety in patients with ankylosing spondylitis by baseline body mass index: A post hoc analysis of phase 2/3 trials. Rheumatol Ther. 2025;12(1):67–84. 10.1007/s40744-024-00726-6
86 Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, et al. Improvement of fatigue in patients with ankylosing spondylitis receiving tofacitinib: Analyses of a phase 3 randomized controlled trial. Rheumatol Ther. 2025;12(1):85–98. 10.1007/s40744-024-00727-5
87 Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, et al. Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis. Arthritis Rheumatol. 2025;77(5):536–46. 10.1002/art.43069
88 Markham A. Baricitinib: First global approval. drugs. 2017;77(6):697–704. 10.1007/s40265-017-0723-3
89 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside perspective of the synthetic and computational toolbox of JAK inhibitors: Recent updates. Molecules. 2020;25(15):3321. 10.3390/molecules25153321. PMid: 32707925.
2 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. 10.1016/s0140-6736(16)31591-4
3 Jethwa H, Bowness P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: New advances and potentials for treatment. Clin Exp Immunol. 2016;183(1):30–36. 10.1111/cei.12670
4 Kim SH, Lee SH. Updates on ankylosing spondylitis: Pathogenesis and therapeutic agents. J Rheum Dis. 2023;30(4):220–33. 10.4078/jrd.2023.0041
5 Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66(2):231–41. 10.1002/art.38291. PMid: 24504793
6 Chen L, Al-Mossawi MH, Ridley A, Sekine T, Hammitzsch A, de Wit J, et al. miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis. Ann Rheum Dis. 2017;76(3):620–5. 10.1136/annrheumdis-2016-210175. PMid: 28039186.
7 Won EJ, Kim HJ, Lee YJ, Kim MJ, Lee HI, Jang HH, et al. CCL20 inhibition for treating inflammation in ankylosing spondylitis. Rheumatology (Oxford). 2023;62(12):4000–5. 10.1093/rheumatology/kead268
8 Yi K, Jo S, Song W, Lee HI, Kim HJ, Kang JH, et al. Analysis of single-cell transcriptome and surface protein expression in ankylosing spondylitis identifies OX40-positive and glucocorticoid-induced tumor necrosis factor receptor-positive pathogenic Th17 cells. Arthritis Rheumatol. 2023;75(7):1176–86. 10.1002/art.42476
9 Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650–7. 10.1093/rheumatology/ket387
10 Giray E, Yağcı İ. Cardiac rehabilitation in a patient with ankylosing spondylitis: A single-program, double-effect. Turk J Phys Med Rehabil. 2019;65(2):194–7. 10.5606/tftrd.2019.2401
11 Ozen S, Ozen A, Unal EU, Tufekcioglu O, Ataman S, Yalcin AP. Subclinical cardiac disease in ankylosing spondylitis. Echocardiography. 2018;35(10):1579–86. 10.1111/echo.14103
12 Linguang Z, Bin J. Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis. J Chinese Pharmaceut Sci. 2018;27(1):59–63. 10.5246/jcps.2018.01.007
13 Ke M, Liu W, Lu H, Pan X, Wu M, Qi N, et al. Breaking boundaries in ankylosing spondylitis: How innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges. Front Immunol. 2025;16:1613502. 10.3389/fimmu.2025.1613502
14 Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 Update. Ann Rheum Dis. 2023;82(1):19–34. 10.1136/ard-2022-223296
15 Martínez-Ramos S, Rafael-Vidal C, Pego-Reigosa JM, García S. Monocytes and macrophages in spondyloarthritis: Functional roles and effects of current therapies. Cells. 2022;11(3):515. 10.3390/cells11030515. PMid: 35159323.
16 Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis—A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. 10.1016/j.semarthrit.2022
17 Garcia-Montoya L, Emery P. Disease modification in ankylosing spondylitis with TNF inhibitors: Spotlight on early phase clinical trials. Expert Opin Investig Drugs. 2021;30(11):1109–24. 10.1080/13543784.2021.2010187
18 Zouris G, Evangelopoulos DS, Benetos IS, Vlamis J. The use of TNF-α inhibitors in active ankylosing spondylitis treatment. Cureus. 2024;16(6):e61500. 10.7759/cureus.61500
19 Kim A, So MW, Lee SG. Association of the driving distance, driving time, and public transit time to the hospital with the persistence of tumor necrosis factor inhibitors in patients with ankylosing spondylitis: A retrospective cohort study. Patient Prefer Adherence. 2025;19:373–82. 10.2147/ppa.S504479
20 Walbaum M, Jana-Valencia N. Aggregate distributional cost-effectiveness analysis of biologics for the treatment of ankylosing spondylitis in Chile. Appl Health Econ Health Policy. 2025;23:905–918. 10.1007/s40258-025-00972-x
21 van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46. 10.1002/art.21913
22 Pelechas E, Voulgari PV, Drosos AA. Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opin Drug Discov. 2021;16(3):227–34. 10.1080/17460441.2021.1846516
23 Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, et al. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): A randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5(4):e215–24. 10.1016/s2665-9913(23)00070-x
24 Machado MA, Maciel AA, de Lemos LL, Costa JO, Kakehasi AM, Andrade EI, et al. Adalimumab in rheumatoid arthritis treatment: A systematic review and meta-analysis of randomized clinical trials. Rev Bras Reumatol. 2013;53(5):419–30.
25 Nakano S, Nakajima A, Sonobe M, Taniguchi S, Yamada M, Yamamoto K, et al. SAPHO syndrome with bone destruction in the lumbar vertebral endplates: A case report. Mod Rheumatol Case Rep. 2025;9(2). 10.1093/mrcr/rxaf013
26 Liu FC, Lu CH, Kuo CF, Liao HT, Lee SS, Su KY, et al. Clinical response to adalimumab therapy and its determinants in patients with radiographic axial spondyloarthritis: A prospective real-world study in Taiwan. Int J Rheum Dis. 2025;28(6):e70285. 10.1111/1756-185x.70285
27 Kwon OC, Lee HS, Yang J, Park MC. Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis. Rheumatology (Oxford). 2025;64(2):588–96. 10.1093/rheumatology/keae003
28 Mu X, Chen S, He C, Li H, Huang Z. Bartonella henselae and Aspergillus flavus coinfection in an immunocompromised patient. Diagn Microbiol Infect Dis. 2025;112(1):116708. 10.1016/j.diagmicrobio.2025.116708
29 Yetkin MF, Benli Ş, Mirza M. Progressive demyelinating disease associated with adalimumab treatment in a patient diagnosed with ankylosing spondylitis. Neurol India. 2025;73(4):791–3. 10.4103/neuroindia.NI_371_20
30 Kwon OC, Lee HS, Yang J, Paul T, Jin H, Lee Y, et al. Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea. Rheumatology (Oxford). 2025;64(6):3518–25. 10.1093/rheumatology/keaf038
31 Cui B, Lin J, Huang Y, Zhu H, Zou J, Qin J, et al. Case report: Dysgeusia, strawberry tongue, and psoriatic eruptions after combination treatment with adalimumab, sulfasalazine, and etoricoxib for ankylosing spondylitis. Front Med (Lausanne). 2025;12:1419922. 10.3389/fmed.2025.1419922
32 Ayari M, Mtir M, Mami I, Rais L, Ben Azouz S, Douggui H, et al. Tubulointerstitial nephritis in ANCA-associated vasculitis as a rare adverse effect of adalimumab: A case report. Curr Drug Saf. 2025;20. 10.2174/0115748863362460250220172535
33 Korkmaz D, Karakoç R, Altunbaş B, Demirtürk N. Candida meningitis accompanied by upper gastrointestinal tract candidiasis in an immunocompromised host. Infect Dis Clin Microbiol. 2025;7(1):97–101. 10.36519/idcm.2025.415
34 Zha M, Ding DD. Immunoglobulin A vasculitis and pustular psoriasis precipitated by Tawon Liar: A case report. J Med Case Rep. 2025;19(1):259. 10.1186/s13256-025-05167-5
35 R, Haughton JM, Goddard EJ, Courmier D, Radziszewski W, Meadows RH, et al. Real-world experience with an adalimumab biosimilar (ABP 501) in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis in Europe: Results from the adelphi disease specific programme. Rheumatol Ther. 2025; 12(3):469-492. 10.1007/s40744-025-00755-9
36 Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–87. 10.1136/annrheumdis-2016-210459
37 Wynne C, Altendorfer M, Sonderegger I, Gheyle L, Ellis-Pegler R, Buschke S, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25(12):1361–70. 10.1080/13543784.2016.1255724
38 Cheng X, Fu Z, Liu J, Cheng B, Shi R, Xu X, et al. Comparative real-world retention rate and safety of biosimilar IBI303 versus Humira in ankylosing spondylitis: A retrospective study. Medicine (Baltimore). 2025;104(26):e43010. 10.1097/md.0000000000043010
39 Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443–53. 10.1016/0161-5890(93)90106-l
40 Deepa AR, Jaleel AA, Ancil A, Debbarma S, Thampi T. Concurrent psoriatic arthritis and ankylosing spondylitis in a middle-aged man: A case report with peripheral joint functional and quality of life assessment. Cureus. 2025;17(2):e79826. 10.7759/cureus.79826
41 Alnaqbi KA, Riaz A, Alaswad M. Paradoxical inflammatory bowel disease induced by golimumab in a patient with ankylosing spondylitis: A case report and systematic review. Cureus. 2025;17(1):e77363. 10.7759/cureus.77363
42 Furusawa H, Shimada S, Sawada A, Tanaka K, Yamamoto K, Miyazaki Y. Composite lymphoma after treatment with infliximab for sarcoidosis and ankylosing spondylitis. Intern Med. 2025;64(1):129–32. 10.2169/internalmedicine.3274-23
43 Moyón M, Añazco JS, Vásconez AE, Larreategui D, Torres MB, Moyón N, et al. Abdominal tuberculosis in a patient with ankylosing spondylitis and infliximab: Is the risk still too great? A case report. J Surg Case Rep. 2025;2025(6):rjaf422. 10.1093/jscr/rjaf422
44 Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis. 2012;71(10):1593–5. 10.1136/annrheumdis-2012-201844
45 Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: Pooled analysis of long-term safety and effectiveness. Adv Ther. 2021;38(8):4366–87. 10.1007/s12325-021-01834-3
46 Kim Y, Choi N, Shin JH, Jo S, Nam B, Kim TH. Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13. J Rheum Dis. 2025;32(2):136–44. 10.4078/jrd.2024.0114
47 Marotte H, Cantagrel A, Coury F, Schaeverbeke T, Assing M, Kessouri M, et al. Real-world effectiveness and safety of infliximab biosimilar CT-P13 for rheumatic diseases: A National Observational Cohort Study (ReFLECT). Adv Ther. 2025;42:4659–4680. 10.1007/s12325-025-03304-6
48 Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56. 10.1056/NEJMoa012664
49 Hassett B, Singh E, Mahgoub E, O’Brien J, Vicik SM, Fitzpatrick B. Manufacturing history of etanercept (Enbrel(®)): Consistency of product quality through major process revisions. MAbs. 2018;10(1):159–65. 10.1080/19420862.2017.1388483
50 Tichý Š, Nekvindová L, Baranová J, Vencovský J, Pavelka K, Horák P, et al. Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A propensity score-matched analysis from the Czech ATTRA registry. Scand J Rheumatol. 2025;54(2):79–86. 10.1080/03009742.2024.2381746
51 Tanchuling RV, Lopez JS, Maliwat RD. Coexistent ankylosing spondylitis and ocular toxocariasis in a pediatric patient manifesting as bilateral panuveitis. Cureus. 2025;17(4):e82767. 10.7759/cureus.82767
52 Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010;2(4):428–39. 10.4161/mabs.12304
53 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): Where we stand today. Hum Vaccin Immunother. 2021;17(6):1586–98. 10.1080/21645515.2020.1836919
54 Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, et al. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther. 2022;24(1):73. 10.1186/s13075-022-02753-6
55 Yu X, Zhong J, Zhuang X, Lin Z, Fu H, Zhang Y. Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: A real-world retrospective and pharmacovigilance study. Front Pharmacol. 2025;16:1533902. 10.3389/fphar.2025.1533902
56 Dhillon S. Certolizumab pegol: A review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014;74(9):999–1016. 10.1007/s40265-014-0239-z
57 Vieujean S, Peyrin-Biroulet L. Triple biologic therapy for refractory Crohn’s disease. J Crohns Colitis. 2025;19(5). 10.1093/ecco-jcc/jjaf067. PMid: 40251965.
58 Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity. 2015;43(4):739–50. 10.1016/j.immuni.2015.08.019
59 Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269–73. 10.1007/s10067-010-1647-4
60 Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–32. 10.1136/annrheumdis-2017-212127
61 van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 Week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–51. 10.1016/s0140-6736(18)31946-9
62 van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79(5):595–604. 10.1136/annrheumdis-2020-216980
63 Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48. 10.1056/NEJMoa1505066
64 Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–20. 10.1002/art.41477
65 Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285. 10.1186/s13075-017-1490-y
66 Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-Week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447–62. 10.1007/s40744-018-0123-5
67 Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: Results from the 52-week, phase III China-centric study, MEASURE 5. Chin Med J (Engl). 2020;133(21):2521–31. 10.1097/cm9.0000000000001099
68 Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, et al. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford). 2025; 64(4):1864–1872. 10.1093/rheumatology/keae432
69 Bounas A, Kandyli A, Katsifi G, Boumpa D, Tektonidou MG, Gazi S, et al. High long-term retention rates of Secukinumab in psoriatic arthritis and ankylosing spondylitis: A 3-year interim analysis from the observational, prospective SERENA study, in Greek patients. Rheumatol Int. 2025;45(5):105. 10.1007/s00296-025-05839-x
70 Felis-Giemza A, Stasiek M, Palej K, Wysmołek-Sołtysik M, Łosoś M, Stańczyk S, et al. Real-world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland. Sci Rep. 2025;15(1):25212. 10.1038/s41598-025-11070-2
71 Neycheva S, Kamburova A. IL-17 Inhibitor secukinumab achieves remission in relapsing polychondritis: A case report. Am J Case Rep. 2025;26:e946916. 10.12659/ajcr.946916
72 Dikmetas O, Kapucu Y, Coşan S, Rustamova N, Ozsoy Z, Kocabeyoglu S, et al. Systemic secukinumab treatment in patients with ankylosing spondylitis: The relationship between systemic and tear proinflammatory cytokines and ocular surface findings—A pilot study. Clin Rheumatol. 2025;44(7):2775–2782. 10.1007/s10067-025-07492-y
73 Li M, Wu P, Yong SB, Leong PY. Case report: Successful treatment of secukinumab-induced SAPHO syndrome with tofacitinib. Int J Rheum Dis. 2025;28(6):e70305. 10.1111/1756-185x.70305
74 Bezerra HKF, Penafort PVM, Alves FA, Prado JD, Vargas PA. First case report of oral histoplasmosis in a patient receiving secukinumab (Cosentyx): Opportunistic infections as complication of emerging immunomodulatory therapies. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025;140(3):e64–e68. 10.1016/j.oooo.2025.04.096
75 van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: Results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515–26. 10.1136/ard-2022-223595
76 Deodhar A, Navarro-Compán V, Poddubnyy D, Gensler LS, Ramiro S, Tomita T, et al. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-Year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 2025;11(1):e005081. 10.1136/rmdopen-2024-005081. PMid: 39890205.
77 Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase iii randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611. 10.1002/art.40753
78 Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85. 10.1136/annrheumdis-2019-216118
79 Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, et al. Ixekizumab for active radiographic axial spondyloarthritis in Chinese patients: 16-and 52-Week results from a phase III, randomized, double-blind, placebo-controlled study. BioDrugs. 2024;38(1):145–56. 10.1007/s40259-023-00625-2
80 Monguchi K, Nakashima C, Hino S, Otsuka A. Alopecia areata observed in a patient receiving ixekizumab: A case report. J Dermatol. 2025;52(7):e634–e636. 10.1111/1346-8138.17768
81 Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019;58(2):197–205. 10.1093/rheumatology/key070
82 Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059–67. 10.1136/ard-2023-224049
83 Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–75. 10.1136/annrheumdis-2020-219012
84 Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib—An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–28.
85 Norton H, Sliwinska-Stanczyk P, Hala T, El-Zorkany B, Stockert L, Mundayat R, et al. Tofacitinib efficacy/safety in patients with ankylosing spondylitis by baseline body mass index: A post hoc analysis of phase 2/3 trials. Rheumatol Ther. 2025;12(1):67–84. 10.1007/s40744-024-00726-6
86 Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, et al. Improvement of fatigue in patients with ankylosing spondylitis receiving tofacitinib: Analyses of a phase 3 randomized controlled trial. Rheumatol Ther. 2025;12(1):85–98. 10.1007/s40744-024-00727-5
87 Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, et al. Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis. Arthritis Rheumatol. 2025;77(5):536–46. 10.1002/art.43069
88 Markham A. Baricitinib: First global approval. drugs. 2017;77(6):697–704. 10.1007/s40265-017-0723-3
89 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside perspective of the synthetic and computational toolbox of JAK inhibitors: Recent updates. Molecules. 2020;25(15):3321. 10.3390/molecules25153321. PMid: 32707925.